OmniAb Inc Dossier
Qualitative Analysis
Business overview
OmniAb, Inc. (NASDAQ: OABI) is a clinical-stage biotechnology company that licenses its proprietary, cutting-edge antibody discovery technology platform to pharmaceutical and biotechnology companies, as well as academic institutions. At the core of OmniAb's offering is its 'Biological Intelligence' platform, which leverages genetically engineered transgenic animals—including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmnidAb—to generate highly diverse, naturally optimized, fully human antibody repertoires. These technologies are designed to accelerate the discovery of next-generation therapeutics, such as bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T therapies. The company's business model aligns its financial success with its partners through upfront access fees, annual maintenance fees, research service revenues, clinical milestone payments, and royalties on commercial sales.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An initiative launched to offer the xPloration screening technology to existing and new partners, enhancing the scalability of OmniAb's technology platforms and creating new business opportunities through durable revenue streams such as consumables and software subscriptions.
Expected impact: Expected to be accretive to both earnings and cash flow in the short- and long-term by generating high-margin recurring revenue.
The launch and commercialization of OmniUltra, a newly introduced transgenic leader platform designed to expand OmniAb's reach into new markets and applications, specifically targeting peptide therapeutics and complex antibody discovery.
Expected impact: Strengthens the company's ability to attract new partners, service new programs, and drive long-term milestone and royalty opportunities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
The partnership combines OmniAb's transgenic antibody discovery solutions with VERAXA's proprietary ADC linker technology and conjugation expertise to co-develop a novel bispecific antibody-drug conjugate (bsADC) program targeting solid tumors.
Terms: The resulting bsADC program will be jointly owned by both parties, and they will share future revenues resulting from the program's continued development, licensing, and commercialization.
A collaboration to discover and generate an antibody-based compound for a specific ion-channel target using OmniAb's platform.
Terms: OmniAb received an upfront payment of $250,000 and is eligible to receive service payments, development, regulatory, and commercialization milestones totaling over $55 million, plus low- to mid-single digit tiered royalties on net sales.
Out-licensing and sale of a legacy small molecule Kv7.2 program to Angelini Pharma, aligning with OmniAb's focus on its core antibody discovery platform.
Terms: OmniAb received an upfront payment of $3 million and is eligible for potential milestones of over $170 million plus royalties.